A New FDA Approved Treatment for Chronic Sinus Disease: What Dupixent's Approval for Allergic Fungal Rhinosinusitis Means for NYC Patients

Key Takeaways

• In February 2026, the FDA approved Dupixent (dupilumab) for adults and children age 6 and older with allergic fungal rhinosinusitis (AFRS) who have a history of sinus surgery, the first medicine ever approved specifically for this condition.
• AFRS is a chronic, allergic type of sinus inflammation caused by hypersensitivity to environmental fungi, commonly causing nasal polyps, thick mucus, congestion, and loss of smell that tends to recur even after surgery.
• In the pivotal trial, patients on dupilumab had a 92% lower relative risk of needing repeat corticosteroids or surgery over 52 weeks compared to patients on placebo, giving patients stuck in a cycle of surgery and polyp regrowth a non-surgical option aimed at the underlying inflammation.
• Not everyone with sinus polyps has AFRS. A proper diagnosis requires imaging and allergy testing, which is exactly the kind of evaluation an allergist is trained to do.

Why this approval matters

If you have ever had sinus surgery for nasal polyps only to watch the congestion, pressure, and loss of smell creep back within a year or two, you already understand the frustration behind this news. AFRS has historically been managed with surgery to physically remove polyps and clear blocked sinuses, followed by oral steroids to calm the inflammation. The problem is that neither approach addresses the allergic reaction driving the disease, so polyps often return and patients end up back in the operating room.

Dupixent's new approval is significant because it targets that underlying allergic inflammation directly, rather than only treating what it produces. For a condition defined by its tendency to come back, a treatment aimed at the root cause is a meaningful shift in how it can be managed.

What AFRS actually is, and how it is different from a typical sinus infection

Not just chronic sinusitis

AFRS is a specific subtype of chronic rhinosinusitis driven by an allergic reaction to fungal spores that are common in the environment, not by an active fungal infection itself. The immune system overreacts to these fungi, producing thick, allergic mucus and nasal polyps that can eventually erode surrounding bone if left untreated long enough.

Common signs include: persistent nasal congestion, thick discolored mucus, facial pressure, reduced or lost sense of smell, and, in more advanced cases, visible facial changes from bone erosion.

What the approval was based on

The FDA reviewed data from the 52 week LIBERTY-AFRS-AIMS trial, which enrolled adults and children with a history of sinus surgery for AFRS. Patients treated with dupilumab showed significant improvement in sinus opacification on CT imaging compared to placebo, along with meaningful reductions in nasal symptoms and nasal polyp size. Most notably, the need for repeat corticosteroids or surgery dropped by 92% relative to placebo over the study period.

What's exciting about this approval is that it gives us a real alternative to the surgery, steroids, recurrence cycle that so many AFRS patients have been stuck in for years. It does not replace the need for surgery in every case, but for patients who keep coming back with new polyps, it finally treats the allergic driver instead of just the aftermath.

— Dr. Robert Tamayev, MD, PhD, Allergy Asthma

Who this is likely to help most

The people most likely to benefit are patients with a confirmed AFRS diagnosis, not just any chronic sinusitis, who have already had at least one sinus surgery, are age 6 or older, and continue to have nasal polyps, congestion, or facial pressure return after surgery. It's also worth discussing for patients who have needed repeated courses of oral steroids to control symptoms, or who are already being treated with dupilumab for a related condition, such as asthma or chronic rhinosinusitis with nasal polyps, and may also have undiagnosed AFRS.

How this affects our patients across NYC

New York's older housing stock, humid summers, and high urban mold exposure make fungal sensitization a real factor for many sinus patients we see across our locations. Anyone who has had sinus surgery in the past and continues to struggle with congestion, facial pressure, or a diminished sense of smell should not assume that repeat surgery is the only option left. A proper allergy workup, including fungal specific testing and sinus imaging, is the first step to finding out whether AFRS is actually driving the recurrence, and whether this new treatment applies.

When to book an evaluation

Consider scheduling a visit if you've had one or more sinus surgeries for nasal polyps and symptoms have returned, if you have chronic sinus congestion along with a reduced or lost sense of smell, if you've needed oral steroids more than once in the past year for sinus symptoms, or if you have known mold or fungal sensitivities along with chronic sinus symptoms. An allergist can order the imaging and allergy testing needed to confirm whether AFRS, rather than a different type of chronic sinusitis, is the underlying cause, and can walk you through whether this new treatment option is appropriate for your case.

Disclaimer: This content is educational and does not substitute for medical advice. Always consult your physician for personal medical questions.